INM - MCAP CO - InMed Pharmaceuticals

InMed Pharmaceuticals is developing a B2B segment for the synthesis of unique cannabinoids to combat glaucoma and neurodegeneration, as confirmed by the price action snapshot on GURU.Markets, where the market capitalization is recorded at 0.01. Drug deliveries rely on strict safety controls and secure transport. Meanwhile, the firm's environmental focus is limited to standard energy saving and waste disposal within its laboratories.

Risk minimization requires selecting assets with stable market value. This metric is calculated as the product of the current share price and the total number of issued securities, reflecting the issuer's aggregate capital. For InMed Pharmaceuticals (INM), this serves as a measure of the stability of Integria patents against the backdrop of low margins in early-stage programs. Monitoring the company's market capitalization allows for an assessment of the business's ability to retain value during market downturns.